Cargando…
Celecoxib Treatment Alters p53 and MDM2 Expression via COX-2 Crosstalk in A549 Cells
Cyclooxygenase-2 (COX-2) has a pivotal role in the pathogenesis of the lung cancer. It is known that COX-2 negatively regulates the activity of a number of tumor suppressors, including p53. Consequently, inhibition of COX-2 signaling is anticipated to be a promising approach to stabilize p53 functio...
Autores principales: | Gharghabi, Mehdi, Rezaei, Farhang, Mir mohammadrezaei, Fereshteh, Ghahremani, Mohammad Hossein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018276/ https://www.ncbi.nlm.nih.gov/pubmed/27642319 |
Ejemplares similares
-
In silico study of fragile histidine triad interaction domains with MDM2 and p53
por: Eslamparast, Ameneh, et al.
Publicado: (2014) -
Multifocal Fixed Drug Eruption with COX-2 Inhibitor-Celecoxib
por: Chugh, Shikha, et al.
Publicado: (2013) -
Selective COX-2 inhibitors, NSAIDs and cardiovascular events – is celecoxib the safest choice?
por: Howes, Laurence Guy
Publicado: (2007) -
Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016) -
Optimized spirooxindole-pyrazole hybrids targeting the p53-MDM2 interplay induce apoptosis and synergize with doxorubicin in A549 cells
por: Islam, Mohammad Shahidul, et al.
Publicado: (2023)